Table 2 Baseline characteristics of patients overall in the different target volume groups
Characteristics | Plan 1(N = 63) | Plan 2(N = 55) | Total(N = 118) | P-value |
|---|---|---|---|---|
Age(years), n (%) | ||||
 Mean (SD) | 51.9 (13.8) | 52.7 (12.8) | 52.3 (13.3) |  |
  ≤ 50 | 25 (39.7) | 20 (36.7) | 45 (38.1) | 0.711 |
  > 50 | 38 (60.3) | 35 (63.6) | 73 (61.9) |  |
Gender, n (%) | Â | Â | Â | 0.278 |
 Female | 16 (25.4) | 19 (34.5) | 35 (29.7) |  |
 Male | 47 (74.6) | 36 (65.5) | 83 (70.3) |  |
BMI, n (%) | ||||
 mean (SD) | 24.5 (3.3) | 25.0 (3.2) | 24.7 (3.3) |  |
  > 24 | 31 (49.2) | 34 (61.8) | 65 (55.1) | 0.169 |
  ≤ 24 | 32 (50.8) | 21 (38.2) | 53 (44.9) |  |
Symptom of onset, n (%) | Â | Â | Â | 0.744 |
 Consciousness disorders | 4 (6.3) | 3 (5.5) | 7 (5.9) |  |
 Dizziness | 5 (7.9) | 4 (7.3) | 9 (7.6) |  |
 Dysfunction | 7 (11.1) | 11 (20.0) | 18 (15.3) |  |
 Epilepsy | 5 (7.9) | 2 (3.6) | 7 (5.9) |  |
 Headache | 30 (47.6) | 27 (49.1) | 57 (48.3) |  |
 Limb weakness | 12 (19.0) | 8 (14.5) | 20 (17.0) |  |
Extent of resection, n (%) | Â | Â | Â | 0.572 |
 GTR | 55 (87.3) | 46 (83.6) | 101 (85.6) |  |
 STR | 8 (12.7) | 9 (16.4) | 17 (14.4) |  |
Pathological diagnosis with WHO 2021, n (%) | Â | Â | Â | 0.958 |
 Astrocytoma | 17 (27.0) | 15 (27.3) | 32 (27.1) |  |
 Oligodendroglioma | 6 (9.5) | 4 (7.3) | 10 (8.5) |  |
 GBM | 40 (63.5) | 36 (65.5) | 76 (64.4) |  |
Laterality, n (%) | Â | Â | Â | 0.414 |
 Left | 34 (54.0) | 23 (41.8) | 57 (48.3) |  |
 Right | 24 (38.1) | 27 (49.1) | 51 (43.2) |  |
 Bilateral | 5 (7.9) | 5 (9.1) | 10 (8.5) |  |
Tumor location, n (%) | Â | Â | Â | 0.962 |
 Frontal | 20 (31.7) | 19 (34.5) | 39 (33.1) |  |
 Occipital | 2 (3.2) | 1 (1.8) | 3 (2.5) |  |
 Parietal | 4 (6.3) | 5 (9.1) | 9 (7.6) |  |
 Temporal | 20 (31.7) | 15 (27.3) | 35 (29.7) |  |
 Cerebellar | 2 (3.2) | 1 (1.8) | 3 (2.5) |  |
 Multiple | 14 (22.2) | 12 (21.8) | 26 (22.0) |  |
 Ventricle | 1 (1.6) | 2 (3.6) | 3 (2.5) |  |
SVZ involvement, n (%) | Â | Â | Â | 0.814 |
 No | 33 (52.4) | 30 (54.5) | 63 (53.4) |  |
 Yes | 30 (47.6) | 25 (45.5) | 55 (46.6) |  |
Cerebral midline involvement, n (%) | Â | Â | Â | 0.509 |
 No | 29 (46.0) | 22 (40.0) | 51 (43.2) |  |
 Yes | 34 (54.0) | 33 (60.0) | 67 (56.8) |  |
Brain cortex involvement, n (%) | Â | Â | Â | 0.413 |
 No | 39 (61.9) | 38 (69.1) | 77 (65.3) |  |
 Yes | 24 (38.1) | 17 (30.9) | 41 (34.7) |  |
MGMT promoter, n (%) | Â | Â | Â | 0.217 |
 Unmethylated | 12 (19.0) | 10 (18.2) | 22 (18.6) |  |
 Methylated | 20 (31.7) | 8 (14.5) | 28 (23.7) |  |
 Unknown | 31 (49.2) | 37 (67.3) | 68 (57.6) |  |
TERT promoter, n (%) | Â | Â | Â | 1.000 |
 Wild type | 11 (17.5) | 7 (12.7) | 18 (15.3) |  |
 Mutated | 18 (28.6) | 10 (18.2) | 28 (23.7) |  |
 Unknown | 34 (53.9) | 38 (69.1) | 72 (61.0) |  |
Ki-67 index (%), n (%) | Â | Â | Â | Â |
 Mean (SD) | 32 (19) | 35 (17) | 0.33 (0.18) |  |
  ≤ 20 | 27 (42.9) | 17 (30.9) | 44 (37.3) | 0.181 |
  > 20 | 36 (57.1) | 38 (69.1) | 74 (62.7) |  |
ATRX, n (%) | Â | Â | Â | 0.275 |
 Wild type | 14 (22.2) | 14 (25.5) | 28 (23.7) |  |
 Mutated | 41 (65.1) | 25 (45.5) | 66 (55.9) |  |
 Unknown | 8 (12.7) | 16 (29.0) | 24 (20.3) |  |
BRAF, n (%) | Â | Â | Â | 0.961 |
 Wild type | 54 (85.7) | 30 (54.6) | 84 (71.8) |  |
 Mutated | 2 (3.3) | 2 (3.6) | 4 (3.4) |  |
 Unknown | 6 (9.5) | 23 (41.8) | 29 (24.8) |  |
P53 expression, n (%) | Â | Â | Â | 0.024 |
 Wild type | 11 (17.5) | 17 (30.9) | 28 (23.7) |  |
 Mutated | 45 (71.4) | 25 (45.5) | 70 (59.3) |  |
 Unknown | 7 (11.1) | 13 (23.6) | 20 (17.0) |  |
CD34, n (%) | Â | Â | Â | 0.001 |
 Wild type | 29 (46.0) | 10 (18.2) | 39 (33.1) |  |
 Mutated | 25 (39.7) | 36 (65.5) | 61 (51.7) |  |
 Unknown | 9 (14.3) | 9 (16.3) | 18 (15.2) |  |
Recurrence, n (%) | Â | Â | Â | 1.000 |
 Recurrence | 48 (76.2) | 42 (76.4) | 90 (76.3) |  |
 No recurrence | 15 (23.8) | 13 (23.6) | 28 (23.7) |  |
Time to radiation(d), ≤ 42d (n%) |  |  |  | 0.655 |
 Astrocytoma | 8 (47.1) | 8 (53.3) | 16 (50.0) |  |
 Oligodendroglioma | 3 (50.0) | 1 (25.0) | 4 (40.0) |  |
GBM | 24 (60.0) | 20 (55.6) | 44 (57.9) | Â |
Pseudoprogression/RN, n (%) | Â | Â | Â | 0.388 |
 Yes | 13 (20.6) | 8 (14.5) | 21 (17.8) |  |
 No | 50 (79.4) | 47 (85.5) | 97 (82.2) |  |